Atazanavir (Indonesian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Atazanavir" in Indonesian language version.

refsWebsite

Global rank Indonesian rank

11nih.gov

4^th place

13^th place

10web.archive.org

1^st place

5doi.org

2^nd place

4^th place

2drugs.com

399^th place

480^th place

1tga.gov.au

3,984^th place

4,575^th place

1canada.ca

1,712^th place

7,978^th place

1europa.eu

68^th place

182^nd place

1handle.net

102^nd place

411^th place

1businesswire.com

615^th place

1,504^th place

1semanticscholar.org

11^th place

330^th place

1fda.gov

447^th place

792^nd place

1drugbank.ca

4,294^th place

9,212^th place

1harvard.edu

18^th place

44^th place

businesswire.com (Global: 615^th place; Indonesian: 1,504^th place)

"Teva Announces Exclusive Launch of a Generic Version of Reyataz in the United States" (Press release). Teva. 27 December 2017. Diarsipkan dari versi aslinya tanggal 4 October 2022. Diakses tanggal 29 September 2021 – via Business Wire.

canada.ca (Global: 1,712^th place; Indonesian: 7,978^th place)

"Product monograph brand safety updates". Health Canada. 7 July 2016. Diarsipkan dari versi aslinya tanggal 29 March 2024. Diakses tanggal 3 April 2024.

doi.org (Global: 2^nd place; Indonesian: 4^th place)

Croom KF, Dhillon S, Keam SJ (May 2009). "Atazanavir: a review of its use in the management of HIV-1 infection". Drugs. 69 (8): 1107–1140. doi:10.2165/00003495-200969080-00009. PMID 19496633. S2CID 195685320.
Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel SS, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW (April 2016). "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing". Clinical Pharmacology and Therapeutics. 99 (4): 363–369. doi:10.1002/cpt.269. PMC 4785051. PMID 26417955.
Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM, Sigal IS (July 1988). "Active human immunodeficiency virus protease is required for viral infectivity". Proceedings of the National Academy of Sciences of the United States of America. 85 (13): 4686–4690. Bibcode:1988PNAS...85.4686K. doi:10.1073/pnas.85.13.4686. PMC 280500. PMID 3290901.
Lv Z, Chu Y, Wang Y (2015). "HIV protease inhibitors: a review of molecular selectivity and toxicity". HIV/AIDS. 7: 95–104. doi:10.2147/HIV.S79956. PMC 4396582. PMID 25897264.
Bold G, Fässler A, Capraro HG, Cozens R, Klimkait T, Lazdins J, Mestan J, Poncioni B, Rösel J, Stover D, Tintelnot-Blomley M, Acemoglu F, Beck W, Boss E, Eschbach M, Hürlimann T, Masso E, Roussel S, Ucci-Stoll K, Wyss D, Lang M (August 1998). "New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development". Journal of Medicinal Chemistry. 41 (18): 3387–3401. doi:10.1021/jm970873c. PMID 9719591.

drugbank.ca (Global: 4,294^th place; Indonesian: 9,212^th place)

"Atazanavir". DrugBank. 9 November 2016. Diarsipkan dari versi aslinya tanggal 9 November 2016.

drugs.com (Global: 399^th place; Indonesian: 480^th place)

"Atazanavir Sulfate". The American Society of Health-System Pharmacists. Diarsipkan dari versi aslinya tanggal 20 December 2016. Diakses tanggal 28 November 2016.
"Atazanavir (Reyataz) Use During Pregnancy". Drugs.com. 27 February 2020. Diarsipkan dari versi aslinya tanggal 1 October 2022. Diakses tanggal 15 September 2020.

europa.eu (Global: 68^th place; Indonesian: 182^nd place)

ema.europa.eu

"Reyataz EPAR". European Medicines Agency (EMA). 2 March 2004. Diarsipkan dari versi aslinya tanggal 3 December 2023. Diakses tanggal 25 May 2024.

fda.gov (Global: 447^th place; Indonesian: 792^nd place)

accessdata.fda.gov

"Reyataz Package Insert" (PDF). Drugs@FDA. Food and Drug Administration. September 2016. Diarsipkan (PDF) dari versi aslinya tanggal 11 November 2016. Diakses tanggal 10 November 2016.

handle.net (Global: 102^nd place; Indonesian: 411^th place)

hdl.handle.net

World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

harvard.edu (Global: 18^th place; Indonesian: 44^th place)

ui.adsabs.harvard.edu

Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM, Sigal IS (July 1988). "Active human immunodeficiency virus protease is required for viral infectivity". Proceedings of the National Academy of Sciences of the United States of America. 85 (13): 4686–4690. Bibcode:1988PNAS...85.4686K. doi:10.1073/pnas.85.13.4686. PMC 280500. PMID 3290901.

nih.gov (Global: 4^th place; Indonesian: 13^th place)

pubmed.ncbi.nlm.nih.gov

Croom KF, Dhillon S, Keam SJ (May 2009). "Atazanavir: a review of its use in the management of HIV-1 infection". Drugs. 69 (8): 1107–1140. doi:10.2165/00003495-200969080-00009. PMID 19496633. S2CID 195685320.
Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel SS, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW (April 2016). "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing". Clinical Pharmacology and Therapeutics. 99 (4): 363–369. doi:10.1002/cpt.269. PMC 4785051. PMID 26417955.
Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM, Sigal IS (July 1988). "Active human immunodeficiency virus protease is required for viral infectivity". Proceedings of the National Academy of Sciences of the United States of America. 85 (13): 4686–4690. Bibcode:1988PNAS...85.4686K. doi:10.1073/pnas.85.13.4686. PMC 280500. PMID 3290901.
Lv Z, Chu Y, Wang Y (2015). "HIV protease inhibitors: a review of molecular selectivity and toxicity". HIV/AIDS. 7: 95–104. doi:10.2147/HIV.S79956. PMC 4396582. PMID 25897264.
Bold G, Fässler A, Capraro HG, Cozens R, Klimkait T, Lazdins J, Mestan J, Poncioni B, Rösel J, Stover D, Tintelnot-Blomley M, Acemoglu F, Beck W, Boss E, Eschbach M, Hürlimann T, Masso E, Roussel S, Ucci-Stoll K, Wyss D, Lang M (August 1998). "New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development". Journal of Medicinal Chemistry. 41 (18): 3387–3401. doi:10.1021/jm970873c. PMID 9719591.

ncbi.nlm.nih.gov

Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel SS, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW (April 2016). "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing". Clinical Pharmacology and Therapeutics. 99 (4): 363–369. doi:10.1002/cpt.269. PMC 4785051. PMID 26417955.
Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM, Sigal IS (July 1988). "Active human immunodeficiency virus protease is required for viral infectivity". Proceedings of the National Academy of Sciences of the United States of America. 85 (13): 4686–4690. Bibcode:1988PNAS...85.4686K. doi:10.1073/pnas.85.13.4686. PMC 280500. PMID 3290901.
Lv Z, Chu Y, Wang Y (2015). "HIV protease inhibitors: a review of molecular selectivity and toxicity". HIV/AIDS. 7: 95–104. doi:10.2147/HIV.S79956. PMC 4396582. PMID 25897264.

nlm.nih.gov

"Atazanavir". MedlinePlus. National Institutes of Health. 15 October 2012. Diarsipkan dari versi aslinya tanggal 2 August 2013. Diakses tanggal 3 August 2013.

dailymed.nlm.nih.gov

"Reyataz- atazanavir capsule, gelatin coated; Reyataz- atazanavir powder". DailyMed. 7 November 2023. Diakses tanggal 17 October 2024.

aidsinfo.nih.gov

"What's New in the Guidelines? | Adult and Adolescent ARV Guidelines". AIDSinfo. Diarsipkan dari versi aslinya tanggal 15 November 2016. Diakses tanggal 10 November 2016.

semanticscholar.org (Global: 11^th place; Indonesian: 330^th place)

api.semanticscholar.org

Croom KF, Dhillon S, Keam SJ (May 2009). "Atazanavir: a review of its use in the management of HIV-1 infection". Drugs. 69 (8): 1107–1140. doi:10.2165/00003495-200969080-00009. PMID 19496633. S2CID 195685320.

tga.gov.au (Global: 3,984^th place; Indonesian: 4,575^th place)

"Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Diarsipkan dari versi aslinya tanggal 6 July 2023. Diakses tanggal 30 March 2024.

web.archive.org (Global: 1^st place; Indonesian: 1^st place)

"Atazanavir". MedlinePlus. National Institutes of Health. 15 October 2012. Diarsipkan dari versi aslinya tanggal 2 August 2013. Diakses tanggal 3 August 2013.
"Atazanavir Sulfate". The American Society of Health-System Pharmacists. Diarsipkan dari versi aslinya tanggal 20 December 2016. Diakses tanggal 28 November 2016.
"Atazanavir (Reyataz) Use During Pregnancy". Drugs.com. 27 February 2020. Diarsipkan dari versi aslinya tanggal 1 October 2022. Diakses tanggal 15 September 2020.
"Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Diarsipkan dari versi aslinya tanggal 6 July 2023. Diakses tanggal 30 March 2024.
"Product monograph brand safety updates". Health Canada. 7 July 2016. Diarsipkan dari versi aslinya tanggal 29 March 2024. Diakses tanggal 3 April 2024.
"Reyataz EPAR". European Medicines Agency (EMA). 2 March 2004. Diarsipkan dari versi aslinya tanggal 3 December 2023. Diakses tanggal 25 May 2024.
"Teva Announces Exclusive Launch of a Generic Version of Reyataz in the United States" (Press release). Teva. 27 December 2017. Diarsipkan dari versi aslinya tanggal 4 October 2022. Diakses tanggal 29 September 2021 – via Business Wire.
"What's New in the Guidelines? | Adult and Adolescent ARV Guidelines". AIDSinfo. Diarsipkan dari versi aslinya tanggal 15 November 2016. Diakses tanggal 10 November 2016.
"Reyataz Package Insert" (PDF). Drugs@FDA. Food and Drug Administration. September 2016. Diarsipkan (PDF) dari versi aslinya tanggal 11 November 2016. Diakses tanggal 10 November 2016.
"Atazanavir". DrugBank. 9 November 2016. Diarsipkan dari versi aslinya tanggal 9 November 2016.

Atazanavir (Indonesian Wikipedia)

businesswire.com (Global: 615th place; Indonesian: 1,504th place)

canada.ca (Global: 1,712th place; Indonesian: 7,978th place)

doi.org (Global: 2nd place; Indonesian: 4th place)

drugbank.ca (Global: 4,294th place; Indonesian: 9,212th place)

drugs.com (Global: 399th place; Indonesian: 480th place)

europa.eu (Global: 68th place; Indonesian: 182nd place)